Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
October 18, 2024 06:50 ET
|
Bright Minds Biosciences
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British...
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
October 16, 2024 10:45 ET
|
Bright Minds Biosciences
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
October 03, 2024 09:00 ET
|
Bright Minds Biosciences
Bright Minds Biosciences Inc. (NASDAQ: DRUG) is excited to announce its participation in the upcoming scientific conferences
Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
September 19, 2024 10:00 ET
|
Bright Minds Biosciences
Bright Minds Biosciences will host the Key Opinion Leader event with leading experts in epilepsy research and treatment on September 25
Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
August 08, 2023 06:50 ET
|
Bright Minds Biosciences
-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders...
Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
July 20, 2023 06:50 ET
|
Bright Minds Biosciences
-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders...
Bright Minds Announces Effective Date of Share Consolidation
July 11, 2023 06:50 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, July 11, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on...
Bright Minds Announces Proposed Share Consolidation
June 22, 2023 06:50 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on...
Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202
April 19, 2023 06:50 ET
|
Bright Minds Biosciences
-- BMB-202 is a highly selective 5-HT2A agonist that exhibits a more than 30-fold selectivity over 5-HT2C and more than 500-fold selectivity over 5-HT2B -- -- BMB-202 is the first clinical...
Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research
April 10, 2023 06:50 ET
|
Bright Minds Biosciences
— Presentation entitled "BMB-101: A selective 5-HT2C agonist in clinical trials with therapeutic utility" — — First-in-human Phase 1 trial for lead program, BMB-101, is underway in Australia — ...